Last reviewed · How we verify
Refractory acute myeloid leukemia
Approved treatments
- Neupogen · University of Chicago
- Neupogen · Amgen
Filgrastim-aafi binds G-CSF receptors on hematopoietic cells, stimulating neutrophil proliferation, differentiation, and functional activation.
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Refractory acute myeloid leukemia patent landscape — cliff calendar, originator estates, attackable patents
- Refractory acute myeloid leukemia treatment landscape brief
- Refractory acute myeloid leukemia treatment updates RSS
Frequently asked questions about Refractory acute myeloid leukemia
What drugs treat Refractory acute myeloid leukemia?
Tracked treatments include Neupogen.
What is the treatment for Refractory acute myeloid leukemia?
Standard treatment for Refractory acute myeloid leukemia includes Neupogen. See the treatment landscape page for first-line, second-line and salvage options.
Related
- Treatment landscape: Refractory acute myeloid leukemia patent cliff · Refractory acute myeloid leukemia CI report
- Treatment: Neupogen · University of Chicago
- Treatment: Neupogen · Amgen
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing